Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials
David Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, Francesco Cosentino, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Jie Liu, Shuai Wang, Christopher P Cannon, VERTIS CV Investigators, David Z I Cherney, Samuel Dagogo-Jack, Darren K McGuire, Francesco Cosentino, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Jie Liu, Shuai Wang, Christopher P Cannon, VERTIS CV Investigators
Abstract
Background: A recent meta-analysis of sodium-glucose cotransporter 2 (SGLT2) inhibitor outcome trials reported that SGLT2 inhibitors were associated with reduction in the risk of adverse composite kidney outcomes, with moderate heterogeneity across the trials; however, the endpoints were defined differently across the trials.
Hypothesis: The apparent heterogeneity of the meta-analysis of kidney composite outcomes of SGLT2 inhibitor trials will be substantially reduced by using a consistent assessment of sustained ≥40% decline in eGFR/chronic kidney dialysis/transplantation/renal death across trials.
Methods: We performed a meta-analysis of kidney composite outcomes from the four SGLT2 cardiovascular outcome trial programs conducted in general type 2 diabetes mellitus populations, which included, as a surrogate of progression to kidney failure, a sustained ≥40% decline in eGFR along with kidney replacement therapy and kidney death. The trials assessed were VERTIS CV (NCT01986881), CANVAS Program (NCT01032629 and NCT01989754), DECLARE-TIMI 58 (NCT01730534), and EMPA-REG OUTCOME (NCT01131676).
Results: Data from the trials comprised 42 516 individual participants; overall, 998 composite kidney events occurred. SGLT2 inhibition was associated with a significant reduction in the kidney composite endpoint (HR 0.58 [95% CI 0.51-0.65]) and with a highly consistent effect across the trials (Q statistic p = .64; I2 = 0.0%).
Conclusions: Our meta-analysis highlights the value of using similarly defined endpoints across trials and supports the finding of consistent protection against kidney disease progression with SGLT2 inhibitors as a class in patients with type 2 diabetes mellitus who either have established atherosclerotic cardiovascular disease or are at high cardiovascular risk with multiple cardiovascular risk factors.
Keywords: SGLT2 inhibitor; kidney disease; kidney failure; meta-analysis; randomized clinical trials; type 2 diabetes mellitus.
Conflict of interest statement
David Z.I. Cherney has received consulting fees or speaking honoraria, or both, from Bristol Myers Squibb, Novo Nordisk, Mitsubishis‐Tanabe, MAZE, Janssen, Bayer, Boehringer Ingelheim‐Eli Lilly, AstraZeneca, Merck & Co., Inc., Prometic, and Sanofi; and has received operating funds from Janssen, Boehringer Ingelheim‐Eli Lilly, Sanofi, AstraZeneca, and Merck & Co., Inc. Samuel Dagogo‐Jack has led clinical trials for AstraZeneca, Novo Nordisk, Inc., and Boehringer Ingelheim; has received fees from AstraZeneca, Boehringer Ingelheim, Janssen, Merck & Co., Inc., and Sanofi; and holds equity interests in Jana Care, Inc. and Aerami Therapeutics. Darren K. McGuire has had leadership roles in clinical trials for AstraZeneca, Boehringer Ingelheim, Eisai, Esperion, GlaxoSmithKline, Janssen, Lexicon, Merck & Co., Inc., Novo Nordisk, CSL Behring, and Sanofi USA; and has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Lilly USA, Merck & Co., Inc., Pfizer, Novo Nordisk, Metavant, Afimmune, and Sanofi. Francesco Cosentino has received fees from Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Merck Sharp & Dohme, Boehringer Ingelheim, Novo Nordisk, and Pfizer; as well as research grants from Swedish Research Council, Swedish Heart & Lung Foundation, and the King Gustav V and Queen Victoria Foundation. Richard Pratley has received the following (directed to his institution): speaker fees from Novo Nordisk; consulting fees from Merck & Co., Inc., Novo Nordisk, Pfizer, Sanofi, Scohia Pharma Inc., and Sun Pharmaceutical Industries; and grants from Lexicon Pharmaceuticals, Hanmi Pharmaceutical Co., Novo Nordisk, Poxel SA, and Sanofi. Weichung J. Shih has received fees for an ertugliflozin advisory board of Merck & Co., Inc., Kenilworth, New Jersey, USA. Robert Frederich and Shuai Wang are employees and shareholders of Pfizer Inc. Mario Maldonado is an employee of MSD UK. He may own stock and/or stock options in Merck & Co., Inc., Kenilworth, New Jersey, USA. Jie Liu is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, USA, and may own stock and/or stock options in Merck & Co., Inc., Kenilworth, New Jersey, USA. Christopher P. Cannon reports grants and personal fees from Pfizer Inc., Amgen, Boehringer Ingelheim, Bristol Myers Squibb, and Janssen; grants and personal fees from Merck & Co., Inc., during the conduct of the trial; grants from Daiichi Sankyo and Novo Nordisk; and personal fees from Aegerion, Alnylam, Amarin, Applied Therapeutics, Ascendia, Corvidia, HLS Therapeutics, Innovent, Kowa, Sanofi, Eli Lilly, and Rhoshan, outside the submitted work.
© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Figures
References
- DK MG, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta‐analysis. JAMA Cardiol. 2020;6(2):148–158. 10.1001/jamacardio.2020.4511.
- Cannon CP, Pratley R, Dagogo‐Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425‐1435.
- Levin A, Agarwal R, Herrington WG, et al. International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int. 2020;98(4):849‐859.
- Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821‐835.
- Cherney DZI, Charbonnel B, Cosentino F, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021;64(6):1256–1267.
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644‐657.
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347‐357.
- Perkovic V, Koitka‐Weber A, Cooper ME, et al. Choice of endpoint in kidney outcome trials: considerations from the EMPA‐REG OUTCOME® trial. Nephrol Dialysis Transplantation Off Pub European Dialysis Transplant Assoc European Renal Assoc. 2020;35:2103‐2111.
- Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37(3/4):256‐266.
- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Stat Med. 2002;21(11):1539‐1558.
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323‐334.
- de Boer IH, Caramori ML, Chan JCN, et al. Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence‐based advances in monitoring and treatment. Kidney Int. 2020;98(4):839‐848.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117‐2128.
- Ferreira JP, Kraus BJ, Zwiener I, et al. Cardio/kidney composite end points: a post hoc analysis of the EMPA‐REG OUTCOME trial. J Am Heart Assoc. 2021;10(7):e020053.
- Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691‐704.
- Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE‐TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606‐617.
Source: PubMed